Product Details
M-Ticagrelor
Ticagrelor90 mg
Tablet
DIN/PIN/NPN
02529769
Manufacturer
Mantra Pharma Inc.
Formulary Listing Date
2022-12-21
Unit Price
0.3960
Amount MOH Pays
0.3960
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
B01AC24
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02368544 | Brilinta | 1.7413 | 0.3960 |
02482630 | Apo-Ticagrelor | 0.3960 | 0.3960 |
02529769 | M-Ticagrelor | 0.3960 | 0.3960 |
02492598 | Taro-Ticagrelor | 0.3960 | 0.3960 |
02531801 | Jamp Ticagrelor | 0.3960 | 0.3960 |
LU Clinical Criteria
LU Code | Auth. Period | Clinical Criteria |
---|---|---|
441 | 1 year | In combination with low-dose ASA for patients with: - Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR - ST-segment elevation myocardial infarction (STEMI); OR - Stent thrombosis while taking clopidogrel plus low-dose ASA. Treatment must be initiated in hospital. Notes: A) *ACS without ST elevation is defined as 2 of 3 of the following criteria: 1. ST-segment changes on electrocardiogram (ECG) indicating ischemia 2. Positive biomarker indicating myocardial necrosis
- Greater than or equal to 60 years of age - Previous MI or coronary artery bypass graft (CABG) - Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels - Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization - Diabetes mellitus - Peripheral artery disease - Chronic renal dysfunction
C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis. D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment. |